UOC
VTAE

UBS O'Connor’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

UBS O'Connor’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-361,675
Closed -$2.4M – 561
2016
Q1 		$2.4M Buy
+361,675
New +$3.29M 0.02% 307

Other funds holding VTAE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS O'Connor's VTAE Position: Q2 2016 in Review

UBS O'Connor sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q2 2016, closing a stake of 361,675 shares — an estimated $2.4M sold.

UBS O'Connor first reported a position in VTAE in Q1 2016 and held it in 1 quarter. The position peaked at $2.4M in Q1 2016. 71 funds tracked by Wall St. Rank hold VTAE as of Q2 2016.

  • UBS O'Connor reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 361,675 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q2 2016, an estimated $2.4M.
  • UBS O'Connor first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2016 and held it in 1 quarter.
  • UBS O'Connor's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $2.4M in Q1 2016.
  • 71 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.